GSK gets approval in China for Nucala
GSK's Sinus Disease Drug Secures Approval In China
On Friday, the China National Medical Products Administration approved GSK plc (NYSE:GSK) Nucala (mepolizumab) as an add-on therapy with intranasal corticosteroids for adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP) for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.
Shares of GSK PLC GSK rose 1.11% to £13.62 Thursday, on what proved to be an all-around favorable trading session for the ...
GSK took center stage last month, forming standout partnerships and alliances across multiple therapeutic areas.
Belantamab mafodotin is under clinical development by GSK and currently in Phase I for Systemic Lupus Erythematosus.
Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. | In this tracker, Fierce Pharma is recording the ...
Drugmaker GSK said, a stamp has been released by India Post to commemorate its 100 years in India. The ₹5 denomination stamp ...
GSK -4178116 (GSK4178116A) is under development for the prevention of varicella (chickenpox) caused by the new strain (US) of varicella-zoster virus (VZV). It is administered through subcutaneous ...
GSK plc (LON:GSK – Get Free Report) insider Jonathan Symonds bought 1,500 shares of the stock in a transaction on Friday, ...
Type a few symbols and Take a Trial. The signals for these will appear immediately on your My Stocks Page; add more too.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback